Market news

Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more

Immuron (NASDAQ:IMRN) has secured exclusive U. S.

MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26. The overall U.S. digestive/gut health supplement market is valued at $4.16 billion (Mordor Intelligence). Immuron is targeting a subset of this market with PROIBS®. PROIBS® is a medical device used for abdominal pai

MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectationsIn February 2026 at the time the Company announced a Strategic Reset, 2H FY26 and FY26 Net Sales were projected to both exceed the prior comparative period (pcp) and Net Sales and Net Profit were all projected to exceed pcp. Immuron has exceeded sales projections with second half growth of

Tipranks Press Release.

MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday, 20th July 2026 (12:30pm Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7639968 This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Stev

Sales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on...